BEAM News and Press, Beam Therapeutics Inc. From 09/15/22

Summary Today, we put mid-cap biotech concern Beam Therapeutics Inc. in the spotlight for the first time. Beam Therapeutics is advancing its pipeline on a wide front and the stock has had a nice ride over the past few months. However, most of Beam's candidates are very early s...

Summary We indicated in our previous update that we needed to observe more constructive bottoming action in ARKK before we would consider re-rating it. We are pleased to highlight that ARKK has likely bottomed out decisively in May. Coupled with a likely peak inflationary environm...

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Wells Fargo 2022 Healthcare Conf...

Shares of the clinical-stage base-editing company Beam Therapeutics (NASDAQ: BEAM) stormed higher through the first four days of trading this week. Specifically, the biotech's stock gained a healthy 16.6%, according to data from S&P Global Market Intelligence . Oddly eno...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don’t miss any of Tom’s picks,  subscribe to his mailing list here . When I...

Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...

Two new Breakout Stocks for Week 33 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +115.9% YTD. This week two picks beat 10% gains in less than week with SELB +34.5% and LYFT +16.2% at peak gains and next top gains in ASIX...

On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N....

Beam Therapeutics press release ( NASDAQ: BEAM ): Q2 GAAP EPS of -$1.02 misses by $0.05 . Revenue of $16.65M beats by $7.21M . Cash, cash equivalents and marketable securities were $1.2 billion as of June 30, 2022, as compared to $965.6 million as of December 3...